Corpus ID: 34792839

CYP2D6 Metabolizer Phenotypes in Patients Undergoing ECT After Antidepressant Therapy

@inproceedings{Mirzakhani2016CYP2D6MP,
  title={CYP2D6 Metabolizer Phenotypes in Patients Undergoing ECT After Antidepressant Therapy},
  author={H. Mirzakhani and Juli{\"e}t van Dormolen and K. Weide and H. Guchelaar and M. V. Noorden},
  year={2016}
}
Introduction Major depressive disorder (MDD) and bipolar disorder (BD) are common mental disorders. According to present guidelines, the effective antidepressant for treatment of MDD and BD for each individual patient is identified through trial and error switching in sequential treatments. A substantial proportion of depressive patients do not benefit from treatment due to ineffectiveness of medication therapy or incurring serious side effects. CYP2D6 variants are associated with metabolic… CONTINUE READING
1 Citations

Tables from this paper

References

SHOWING 1-10 OF 68 REFERENCES
Pharmacogenetics of antidepressant medication intolerance.
  • 252
  • PDF
The role of pharmacogenetics in the treatment of depression and anxiety disorders
  • 66
Clinical features of bipolar depression versus major depressive disorder in large multicenter trials.
  • 175
Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients
  • 76
CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study
  • 187